Exploring Clinical Characteristics of Liver Disease Patients Based on Digestive Metabolic Exhaled Air

Launched by SHANGHAI ZHONGSHAN HOSPITAL · May 5, 2025

Keywords

ClinConnect Summary

This clinical trial is focused on understanding liver disease, specifically cirrhosis, by analyzing the breath of patients. Cirrhosis is a serious condition that affects the liver and can occur due to long-term liver damage. The researchers want to see how the gut bacteria (the microbiota) and certain gases in the breath, like nitric oxide and hydrogen, relate to the health of the liver. By studying these breath markers along with other tests, they hope to find new ways to diagnose liver disease early and improve treatments, which could help patients live longer and better lives.

To participate in this trial, patients need to be diagnosed with chronic liver disease or cirrhosis and should be able to complete a breath test shortly after being admitted to the hospital. However, those who have taken antibiotics recently or have severe lung conditions are not eligible to join. Participants can expect to undergo a breath test that will help researchers gather important information about their liver health, contributing to future advancements in liver disease care.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • ① Patients diagnosed with chronic liver disease or cirrhosis through liver biopsy pathology or clinical laboratory and imaging examinations;
• • ② Undergo molecular breath testing within one week of admission.
• Exclusion Criteria:
• • Patients who have received antibiotic treatment within one month; ② Patients with severe pulmonary diseases, such as chronic obstructive pulmonary disease (COPD), asthma, or lung malignancies that have not been clinically cured; ③ Patients who are unable to successfully complete the molecular breath test.